| Assessment Status | Rapid Review complete |
| HTA ID | 22056 |
| Drug | Buprenorphine |
| Brand | Buvidal® |
| Indication | Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
| Assessment Process | |
| Rapid review commissioned | 09/08/2022 |
| Rapid review completed | 23/09/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Buvidal® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. April 2024
